Acurx Prescription drugs Inc ACXP shares are buying and selling decrease by 30% to 46 cents throughout Friday’s session after the corporate introduced a $1.1 million registered direct providing.
What To Know: Acurx Prescription drugs, a late-stage biopharma firm, has entered right into a definitive settlement for a registered direct providing of two.75 million widespread shares at 40 cents per share, elevating roughly $1.1 million.
Moreover, the corporate will concern unregistered short-term warrants in a non-public placement, permitting the acquisition of as much as 8.24 million shares on the similar value, pending stockholder approval.
The providing, anticipated to shut by March 10, is led by H.C. Wainwright & Co. Acurx plans to make use of the proceeds for working capital and common company functions.
Learn Additionally: Nasdaq Plans 24-Hour Buying and selling To Faucet International Investor Demand
Based on information from Benzinga Professional, ACXP has a 52-week excessive of $3.32 and a 52-week low of $0.60.
Momentum2.70
Progress–
High quality–
Worth–
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
